Professor Zhao Weili, bottom, from Ruijin Hospital at the Shanghai Jiao Tong University School of Medicine speaks during the online session. [Photo provided to chinadaily.com.cn]
Top scholars from China and abroad met online to discuss academic developments with a focus on cutting-edge technologies contributing to global medical development and worldwide health during the 26th Asia-Pacific Bone and Marrow Transplantation Congress, which was held from Oct 14 to 17.
In the CAR-T academic session on Oct 16, international experts and scholars gave presentations and exchanged views on the role of CAR-T cell therapy in hematological tumors. Professor Zhao Weili from Ruijin Hospital of the Shanghai Jiao Tong University School of Medicine made a closing speech and shared the Chinese experience with CAR-T therapy.
Zhao discussed the treatment of two diffuse large B-cell lymphoma patients in China who received CAR-T cell therapy. Through a comprehensive presentation of patient characteristics, treatment process, adverse events management post CAR-T, and efficacy assessment, she demonstrated the outstanding efficacy of CAR-T for the treatment of lymphoma, the valuable Chinese experience in the whole process of CAR-T management, as well as current challenges and effective strategies to tackle them.
